Brief: Portage Biotech Collaborates With Merck To Study 2 Next-Gen Adenosine Antagonists In Combination With Keytruda In Solid Tumors
05/09/2023 13:22
Sept 5 (Reuters) - Merck & Co Inc MRK.N :
* PORTAGE BIOTECH ANNOUNCES COLLABORATION WITH MERCK TO
EVALUATE
TWO NEXT-GENERATION ADENOSINE ANTAGONISTS IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB) IN SOLID TUMORS
* PORTAGE BIOTECH INC - UNDER TERMS OF AGREEMENT, MERCK WILL
PROVIDE KEYTRUDA FOR PORTAGE BIOTECH'S ADPORT-601
Source text for Eikon: ID:nGNX8wNyfG
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsAlpha Compute Corp expected to post a loss of $3.50 a share - Earnings Preview
NASDAQ RESUMED AT 10:18 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:13 AM
Brief: Alpha Compute Signs Binding Gpu Contract, Leasing ALPHA-03 Cluster Under Four-Year, $81.7 Million Agreement In Its Missouri Superintelligence Factory
Alpha Compute Corp expected to post a loss of $3.50 a share - Earnings Preview